Sporadic RCC: Abnormalities in histone-modifying genes

Ruhee Dere, Thai H Ho

Research output: Book/ReportBook

Abstract

Renal cell carcinoma (RCC) is one of the top ten leading causes of cancer death, affecting more than 50,000 patients annually. The median survival of patients with metastatic disease is approximately 2 years with systemic therapy, and the most common histology is clear cell renal cell carcinoma (ccRCC). The molecular mechanism is linked to the inactivation of the von Hippel-Lindau tumor suppressor gene (VHL), which encodes for an oxygen sensor that regulates degradation of the HIF (hypoxia-inducible factor) transcription factor (Latif et al., Science 260(5112):1317-1320, 1993). HIF transactivates target genes involved in cellular adaptation to hypoxia. The mammalian target of rapamycin (mTOR) signaling cascade is often stimulated in ccRCC, and activation of the mTOR kinase pathway further augments HIF levels to subsequently activate HIF-dependent transcription (Barthelemy et al., Crit Rev Oncol Hematol 88(1):42-56, 2013). The elucidation of VHL function and mTOR pathway activation led to the discovery of VEGF and mTOR inhibitors for RCC treatment. Recently, secondary mutations identified in histone-modifying enzymes suggest that chromatin remodeling and alterations of histone modifications may play a role in RCC pathogenesis and prognosis with distinct epigenetic phenotypes. This chapter will focus on summarizing the more prevalent genetic mutations and possible aberrant signaling pathways that contribute to metastatic ccRCC.

Original languageEnglish (US)
PublisherSpringer New York
Number of pages13
ISBN (Print)9781493916221, 9781493916214
DOIs
StatePublished - Jan 1 2015

Fingerprint

Renal Cell Carcinoma
Histones
Sirolimus
Genes
Transcription Factors
Histone Code
Mutation
Chromatin Assembly and Disassembly
Tumor Suppressor Genes
Epigenomics
Vascular Endothelial Growth Factor A
Cause of Death
Histology
Phosphotransferases
Hypoxia
Oxygen
Phenotype
Survival
Enzymes
Therapeutics

Keywords

  • BAP1
  • Epigenetics
  • PBRM1
  • Renal cell carcinoma
  • SETD2

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sporadic RCC : Abnormalities in histone-modifying genes. / Dere, Ruhee; Ho, Thai H.

Springer New York, 2015. 13 p.

Research output: Book/ReportBook

Dere, Ruhee ; Ho, Thai H. / Sporadic RCC : Abnormalities in histone-modifying genes. Springer New York, 2015. 13 p.
@book{82d19290542f48f091b96dc0a99b8819,
title = "Sporadic RCC: Abnormalities in histone-modifying genes",
abstract = "Renal cell carcinoma (RCC) is one of the top ten leading causes of cancer death, affecting more than 50,000 patients annually. The median survival of patients with metastatic disease is approximately 2 years with systemic therapy, and the most common histology is clear cell renal cell carcinoma (ccRCC). The molecular mechanism is linked to the inactivation of the von Hippel-Lindau tumor suppressor gene (VHL), which encodes for an oxygen sensor that regulates degradation of the HIF (hypoxia-inducible factor) transcription factor (Latif et al., Science 260(5112):1317-1320, 1993). HIF transactivates target genes involved in cellular adaptation to hypoxia. The mammalian target of rapamycin (mTOR) signaling cascade is often stimulated in ccRCC, and activation of the mTOR kinase pathway further augments HIF levels to subsequently activate HIF-dependent transcription (Barthelemy et al., Crit Rev Oncol Hematol 88(1):42-56, 2013). The elucidation of VHL function and mTOR pathway activation led to the discovery of VEGF and mTOR inhibitors for RCC treatment. Recently, secondary mutations identified in histone-modifying enzymes suggest that chromatin remodeling and alterations of histone modifications may play a role in RCC pathogenesis and prognosis with distinct epigenetic phenotypes. This chapter will focus on summarizing the more prevalent genetic mutations and possible aberrant signaling pathways that contribute to metastatic ccRCC.",
keywords = "BAP1, Epigenetics, PBRM1, Renal cell carcinoma, SETD2",
author = "Ruhee Dere and Ho, {Thai H}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1622-1_6",
language = "English (US)",
isbn = "9781493916221",
publisher = "Springer New York",

}

TY - BOOK

T1 - Sporadic RCC

T2 - Abnormalities in histone-modifying genes

AU - Dere, Ruhee

AU - Ho, Thai H

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Renal cell carcinoma (RCC) is one of the top ten leading causes of cancer death, affecting more than 50,000 patients annually. The median survival of patients with metastatic disease is approximately 2 years with systemic therapy, and the most common histology is clear cell renal cell carcinoma (ccRCC). The molecular mechanism is linked to the inactivation of the von Hippel-Lindau tumor suppressor gene (VHL), which encodes for an oxygen sensor that regulates degradation of the HIF (hypoxia-inducible factor) transcription factor (Latif et al., Science 260(5112):1317-1320, 1993). HIF transactivates target genes involved in cellular adaptation to hypoxia. The mammalian target of rapamycin (mTOR) signaling cascade is often stimulated in ccRCC, and activation of the mTOR kinase pathway further augments HIF levels to subsequently activate HIF-dependent transcription (Barthelemy et al., Crit Rev Oncol Hematol 88(1):42-56, 2013). The elucidation of VHL function and mTOR pathway activation led to the discovery of VEGF and mTOR inhibitors for RCC treatment. Recently, secondary mutations identified in histone-modifying enzymes suggest that chromatin remodeling and alterations of histone modifications may play a role in RCC pathogenesis and prognosis with distinct epigenetic phenotypes. This chapter will focus on summarizing the more prevalent genetic mutations and possible aberrant signaling pathways that contribute to metastatic ccRCC.

AB - Renal cell carcinoma (RCC) is one of the top ten leading causes of cancer death, affecting more than 50,000 patients annually. The median survival of patients with metastatic disease is approximately 2 years with systemic therapy, and the most common histology is clear cell renal cell carcinoma (ccRCC). The molecular mechanism is linked to the inactivation of the von Hippel-Lindau tumor suppressor gene (VHL), which encodes for an oxygen sensor that regulates degradation of the HIF (hypoxia-inducible factor) transcription factor (Latif et al., Science 260(5112):1317-1320, 1993). HIF transactivates target genes involved in cellular adaptation to hypoxia. The mammalian target of rapamycin (mTOR) signaling cascade is often stimulated in ccRCC, and activation of the mTOR kinase pathway further augments HIF levels to subsequently activate HIF-dependent transcription (Barthelemy et al., Crit Rev Oncol Hematol 88(1):42-56, 2013). The elucidation of VHL function and mTOR pathway activation led to the discovery of VEGF and mTOR inhibitors for RCC treatment. Recently, secondary mutations identified in histone-modifying enzymes suggest that chromatin remodeling and alterations of histone modifications may play a role in RCC pathogenesis and prognosis with distinct epigenetic phenotypes. This chapter will focus on summarizing the more prevalent genetic mutations and possible aberrant signaling pathways that contribute to metastatic ccRCC.

KW - BAP1

KW - Epigenetics

KW - PBRM1

KW - Renal cell carcinoma

KW - SETD2

UR - http://www.scopus.com/inward/record.url?scp=84944525171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944525171&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1622-1_6

DO - 10.1007/978-1-4939-1622-1_6

M3 - Book

AN - SCOPUS:84944525171

SN - 9781493916221

SN - 9781493916214

BT - Sporadic RCC

PB - Springer New York

ER -